Citations

Clear

951 citation(s) found for "Cohen, M".

2026 Latin American consensus for the management of patients with hypertension and cardio-renal and metabolic disturbances: endorsed by the Latin American Society of Hypertension, the Iberoamerican Hypertension League, and the World Hypertension League
Coca, António , Sanchez, Ramiro , Salazar, Dora I. Molina De, Peñaherrera, Ernesto , Alcocer, Luis, Barbosa, Eduardo, Grassi, Guido, Lopez-Jaramillo, Patricio, Lurbe, E, Parra-Carrillo, José, Ramírez, Agustín, Redón, Josep, Sebba-Barroso, Weimar, Acosta, Andres, Aristizábal, Dagnóvar, Bryce, Alfonso, Cerezo, Gustavo, COHEN, RICARDO V., Diaz-Velasco, Margarita E., Hernández, Rafael, Lanas, Fernando, Machado, Livia, Musso, Carla, Piskorz, Daniel, Ponte-Negreti, Carlos I., Ramos, Olga, Sánchez, María J., Valdez, Osiris, Vicario, Augusto, Villar, Raul, Parati, Gianfranco, Whelton, Paul K., Wyss, Fernando, Mancia, Giuseppe, SALAZAR, DORA INES MOLINA DE, Grassi, Guido M. , López‐Jaramillo, Patricio , Lurbe, Empar , Parra-Carrillo, José Z., Redón, Josep , Sebba-Barroso, Weimar K., Cerezo, Gustavo Hernán, COHEN, RICARDO VITOR , Diaz-Velazco, Margarita E., Hernández, Rafael Hernández, Laņas, Fernando , Piskorz, Daniel , Ponte-Negretti, Carlos Ignacio , Sanchez, María J., Valdez-Tiburcio, Osiris , Villar, Raúl , Parati, Gianfranco , Whelton, Paul K. , Mancia, Giuseppe

Mayo Clinic

Journal of Hypertension | March 24, 2026 | Volume: 44 | Issue: 6 | Pages: 885-910

10.1097/hjh.0000000000004290 | PMID 41875318 Get It

Hypertension is the main risk factor for cardiovascular disease (CVD), affecting 20–40% of Latin American (LATAM) adults, and responsible for more than two million deaths annually due to CVD. The different ethnic, economic, geographic, and cultural characteristics of the LATAM population influence the high prevalence of all cardiovascular risk factors (CVRF), particularly metabolic disturbances such as type 2 diabetes (DM2), obesity and the metabolic syndrome. Their main determinants in LATAM includes environment, food quality, social inequity, low education, political aspects, contextual behaviour, and genetics. The prevalence of overweight and obesity in LATAM increased during the last four decades reaching figures of 10–20% in childhood, 30–40% in adolescence, and 60–70% in adults. Many studies in the region have reported the extremely low rates of awareness, treatment, and control of CVRF in the general population of LATAM, particularly in patients with metabolic disorders, and the consequent high cardiovascular morbidity and mortality. This 2026 LATAM consensus is developed by a large group of experts from different LATAM countries, the USA and Europe, representing areas of internal medicine, cardiology, nephrology, endocrinology, geriatrics, paediatrics, pharmacology, and epidemiology. A careful search for novel studies in LATAM, together with new evidence that has emerged since the 2019 LATAM consensus, support the statements and recommendations in the current report. This update aims to provide clear and useful recommendations for health professionals to improve awareness, treatment, and control of hypertension and associated CVRF in the region.
Clinical Criteria for the Definition of Refractory Septic Shock: A Joint Delphi Consensus from the Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM)
Myatra, Sheila Nainan , Dugar, Siddharth , Russell, Lene , Delamarre, Louis , Sharif, Sameer , Chew, Michelle S. , Gong, Michelle N. , Hernández, Glenn , Martín‐Loeches, Ignacio , Dünser, Martin W., Einav, Sharon , Hamzaoui, Olfa, Frazee, Erin N. , Busse, Laurence W. , Deutschman, Clifford S. , Holder, Andre L. , Nazer, Lama , Nunnally, Mark , Rincon, Teresa , Seymour, Christopher W. , Besen, Bruno Adler Maccagnan Pinheiro , Finfer, Simon , Machado, Flávia Ribeiro , Mer, Mervyn , Young, Paul J. , Khanna, Ashish , Dugar, Siddharth , Wieruszewski, Patrick M , Russell, Lene , Evans, Laura , Delamarre, Louis , Sharif, Sameer , Chew, Michelle S , Gong, Michelle Ng , Hernández, Glenn , Schorr, Christa , Lakbar, Ines , Smith, Susan E , Martin-Loeches, Ignacio , Annane, Djillali , Balik, Martin , Cecconi, Maurizio , De Backer, Daniel , Donadello, Katia , Einav, Sharon , Ferrer, Ricard , Juffermans, Nicole , Hamzaoui, Olfa , Landoni, Giovanni , Levy, Bruno , McKenzie, Cathrine , Monnet, Xavier , Ostermann, Marlies , Spies, Claudia D , Singer, Mervyn , Theodorakopulou, Maria , Topeli, Arzu , Frazee, Erin N , Bauer, Seth R , Busse, Laurence W , Coopersmith, Craig M , Deutschman, Clifford , Holder, Andre L , Kamaleswaran, Rishikesan , Legrand, Matthieu , Martin, Greg S , Maves, Ryan C , Nazer, Lama , Nunnally, Mark E , Prescott, Hallie C , Rincon, Teresa , Sacha, Gretchen , Seymour, Chris W , Arabi, Yaseen M , Besen, Bruno Amp , Cavalcanti, Alexandre Biasi , Deane, Adam M , Finfer, Simon , Hammond, Naomi , Ibarra-Estrada, Miguel , Kattan, Eduardo , Kotani, Yuki , Machado, Flavia R , Ospina-Tascón, Gustavo A , Mer, Mervyn , Young, Paul J , Rochwerg, Bram , Khanna, Ashish K , Léone, Marc , Wieruszewski, Patrick M. , Smith, Susan , Backer, Daniel De , Dünser, Martin W. , Lévy, Bruno , McKenzie, Cathrine , Ostermann, Marlies , Spies, Claudia , Kamaleswaran, Rishikesan , Legrand, Matthieu , Martin, Greg S. , Maves, Ryan C. , Prescott, Hallie C. , Arabi, Yaseen M. , Deane, Adam M. , Hammond, Naomi

Mayo Clinic

Critical Care Medicine | March 24, 2026 | Volume: 54 | Issue: 5 | Pages: 1073-1091

10.1097/ccm.0000000000007124 | PMID 41873857 Get It

OBJECTIVE: A definition of refractory septic shock is necessary to guide diagnosis, management, prognostication, research, and future guidelines for this most severe form of the disease. We sought to achieve consensus on clinical criteria that would be used to define refractory septic shock. DESIGN: Review of literature, expert panel position statements, and Delphi rounds with an international expert group. SETTING: Consensus was defined as having at least 75% of panellists in agreement or disagreement on the three highest or lowest levels of a 7-point Likert scale or based on responses to single- or multiple-choice questions, respectively. SUBJECTS: A panel of multinational, multiprofessional and multidisciplinary critical care experts assembled by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine (57 invitations and 56 participants). MEASUREMENTS AND MAIN RESULTS: A five-round Delphi process was conducted for consensus and stability. The steering committee proposed 34 statements, and five of them were rejected by panel experts after round 2. Among 29 statements selected from eight domains, consensus was reached for 13. The panel agreed on the need for a comprehensive consensus set of clinical criteria for refractory septic shock. Markers of organ dysfunction (75%, 2 rounds), tissue perfusion (91.1%, 2 rounds) including lactate (94.6%, 2 rounds) and capillary refill time (76.8%, 2 rounds), assessment of fluid-responsiveness after initial resuscitation (92.9%, 5 rounds), and use of vasoactive drugs at norepinephrine equivalents greater than 0.5 µg/kg/min (75.0%, 3 rounds), were selected as clinical criteria of refractory septic shock. The use of critical care ultrasound (CCUS) (92.9%, 3 rounds) was the single diagnostic modality that reached a consensus-based agreement. CONCLUSIONS: A consensus for 13 criteria to frame the definition of refractory septic shock was reached. Refractory septic shock is characterised by persistently elevated lactate concentrations and or prolonged capillary refill time in patients with septic shock who are fluid unresponsive, require a norepinephrine base equivalent dose greater than 0.5 micrograms per kilogram per minute, and undergo CCUS assessment when mixed shock is suspected.
Ustekinumab for ileal stricturing Crohn’s disease—an international multicenter retrospective cohort study
Ouali, Sara El , Baker, Mark E, Lu, Cathy , Medellin, A, Bruining, David H, Fletcher, Joel G. , Inoue, Aki, Regueiro, Miguel, Ottichilo, Ronald K. , Schoenoff, Shayla, Rosentreter, Ryan E., Qazi, Taha , Holubar, S. D., Gauriloff, Samantha, Gandhi, Namita , Cohen, Benjamin L, Balci, Numan, Rieder, Florian, Regueiro, Miguel , Lu, Cathy , El Ouali, Sara , Regueiro, Miguel , Qazi, Taha , Sleiman, Joseph , Holubar, Stefan D , Rieder, Florian , Fletcher, Joel G , Baker, Mark E. , Medellin, Alexandra , Bruining, David H. , Inoue, Aki, Bena, Jim , Sleiman, Joseph , Holubar, Stefan D. , Cohen, Benjamin L, Goren, Idan , Rieder, Florian

Mayo Clinic

Journal of Crohn's and Colitis | March 23, 2026 | Volume: 20 | Issue: 3 | Pages: No page available

10.1093/ecco-jcc/jjag038 | PMID 41934342 Get It

Abstract Background & Aims Stricturing Crohn’s disease (CD) is a significant problem, and no selective anti-fibrotic therapies are available. Anti-inflammatory approaches are the mainstay of medical treatment. However, data on the efficacy of ustekinumab (USTE) in ileal stricturing CD are lacking. Our aim was to assess its efficacy in this setting. Methods We performed an international multicenter observational cohort study evaluating adult CD patients who received USTE within 6 months of imaging-confirmed symptomatic stricturing small bowel disease. Outcomes were rates of endoscopic balloon dilation (EBD), surgery, intervention (defined as the composite need for EBD or surgery), recurrent obstructive symptoms, and USTE persistence. Results Fifty-seven patients were included (51% female, median age 43 years). Median follow-up was 17 months. Intervention rates were 35%, 45%, and 69% of patients, at 12, 24, and 48 months, respectively. USTE persistence was 78%, 76%, and 52% at 12, 24, and 48 months. Estimated obstructive symptoms rates were 31% and 49% at 12 and 24 months, respectively. EBD within 6 months prior to starting USTE was associated with an increased risk of intervention. Increased bowel wall thickness on imaging, prior biologic use, and obstructive symptom duration were associated with USTE discontinuation. Occurrence of obstructive symptoms during treatment was associated with prior biologic use, EBD within 6 months of starting USTE, and a lower BMI. Conclusions USTE appears to be an appropriate medical option in biologic-experienced CD patients with ileal strictures. Further prospective data are needed to better define outcomes and predictors of response in this setting.
Translating AI research into reality: summary of the 2025 voice AI Symposium and Hackathon
Cruz, Samantha Salvi, Toghranegar, Jamie , MacDonald, Bob, Speights, Marisha, Noufi, Camille , Fagherrazi, Guy, Blatter, Alden, Arienzo, Arianna, Baur, Sebastien , Wetstone, Katie , Peller, Julian, Au, R., Botha, Hugo, Lahav, Amir, Hemmerling, Daria , Anibal, James, Coleman, Oita C, Gallois, Hortense , Martinez, Sophia Avila, Mahapatra, Nihar R. , Sara, Jaskanwal Deep Singh , Mathur, Aarush, Patel, Rupal , Zieliński, Konrad , Lerner-Ellis, Jordan, Cong, Yan , Ngo, Hoan, Talkar, Tanya , Hale, Greg, Comito, Keith, Ghosh, Satrajit, Watts, Stephanie, Powell, Maria, Bélisle-Pipon, Jean-Christophe, Krussel, Andrea, Mahapatra, Ishaan, Bahr, Ruth Huntley , Kostelnik, Cynthia, Dorsey, Katie, John, MyVan, Curp, Kathleen, Rameau, Anaïs, Bensoussan, Yaël , Singh Sara, Jaskanwal Deep, Hemmerling, Daria , Cruz, Samantha Salvi, Malin, Bradley , Mehra, Tarun , Speights, Marisha L., Fossat, Yan , Cummins, Nicholas , Elbeji, Abir , Gelbard, Alexander , Au, Rhoda , Botha, Hugo, Lahav, Amir, Catania, Fabio , Saha, Shumit , Kourtis, Lampros C , Lerner‐Ellis, Jordan P. , Watts, Stephanie, Bedrick, Steven , Belisle-Pipon, Jean-Christophe , Krussel, Andrea, Mahapatra, Ishaan , Hanna, Karim , Rameau, Anais

Mayo Clinic

Frontiers in Digital Health | March 16, 2026 | Volume: 8 | Issue: No issue available | Pages: No page available

10.3389/fdgth.2026.1754426 | PMID 41918982 Get It

The 2025 Voice AI Symposium represented a transition from conceptual research to clinical implementation in vocal biomarker science. Hosted by the NIH-funded Bridge2AI-Voice consortium, the meeting convened global experts to address the methodological, ethical, and translational challenges of integrating voice-based artificial intelligence (AI) into healthcare. This mini-review synthesizes symposium insights across six domains: multimodal integration, FAIR (Findable, Accessible, Interoperable, Reusable) and CARE (Collective Benefit, Authority to Control, Responsibility, Ethics) data governance, clinical translation, interdisciplinary training, and cross-sector innovation. Research presented demonstrated voice as a latent, multimodal biomarker reflecting neurological, cardiopulmonary, and psychological states, while discussions emphasized ethical data practices and human-centered design. The implementation-focused panels underscored the importance of workflow alignment and usability for adoption in real-world care. Collectively, the symposium reflects a field advancing toward translational readiness and ethical accountability, positioning voice AI as a scalable, inclusive tool for next-generation healthcare.
Gene Portals: A Framework for Integrating Clinical, Functional, and Structural Evidence into Rare Disease Variant Classification
Brünger, Tobias , Krey, Ilona , Kim, Suyeon, Klöckner, Chiara , Myers, Scott J, Johannesen, Katrine M. , Stefanski, Arthur , Taylor, Gary, Macnee, Marie , Dahl, Rebekka S., Yuan, Hongjie, Kim, Sukhan, Helbig, Ingo, Pan, Jen, Kurganov, Erkin , Baez, David, Zuberi, Sameer M., Lerche, Holger, May, Patrick, Ivaniuk, Alina, Meskis, Mary Anne , Hood, Veronica , Schust, Leah F., Freed, Amber, Froelich, Steven, Deng, Alexander T., Bouman, Arjan , Hajianpour, M.J. , Pal, Deb K. , Danvoye, Leslie, Lederer, Damien , BALCI, TUĞÇE, Hagebeuk, Eveline , Heidlebaugh, Alexis R. , Oetjens, Kathryn F., Striano, Pasquale, Williams, Sarah Drewes, Engelen, Kalene van , Howell, Katherine B. , Khoury, Jean , Benke, Tim A., Strehlow, Vincent , Platzer, Konrad, Ramsey, Amy J, Manaster, Lisa, Malepati, Sunitha, Fox, Pangkong M., Noebels, Jeffrey, Chung, Wendy, Poduri, Annapurna, Stripe, Laina Lusk, Ruggiero, Sarah M., Cohen, Stacey, Wilmarth, Olivia, Prentice, Anna Jenne, Cha, Esther, Budnik, Nikita , Kramer, Audra A. , Gh, Zhang, Palotie, Aarno, Daly, Mark J., Møller, R., Lemke, Johannes R., Lal, Dennis , Møller, Rikke S. , May, Patrick , Bruenger, Tobias , Pan, Jen Q , Farrant, Mark , Wyllie, David J A , Bosselmann, Christian , Mantegazza, Massimo , May, Patrick , Ivaniuk, Alina , Goodspeed, Kimberly , Trinidad, Marena , Aledo-Serrano, Ángel , Pal, Deb K , Platzer, Konrad , Ruggiero, Sarah M , Daly, Mark J. , George, Alfred L , Brunklaus, Andreas , Møller, Rikke S , Myers, Scott J. , Taylor, Gary, Pérez‐Palma, Eduardo , Schorge, Stéphanie , Dahl, Rebekka S. , Perszyk, Riley E. , Bajaj, Sunanjay , Helbig, Ingo , Wollmuth, Lonnie P. , Báez-Nieto, David , Zuberi, Sameer M. , Boßelmann, Christian M. , Mantegazza, Massimo , Cestèle, Sandrine , Ivaniuk, Alina , Kang, Jing‐Qiong , Gati, Cornelius , Montanucci, Ludovica , Wüster, Arthur , Deng, Alexander T. , Borovikov, Artem O. , Sharkov, Artem A. , Bouman, Arjan , Hoffman, Trevor L. , Howell, Katherine B. , Benke, Tim A. , Platzer, Konrad , Ramsey, Amy J. , Fox, Pangkong , Noebels, Jeffrey L. , Chung, Wendy K. , Poduri, Annapurna , Lusk, Laina G. , Cohen, Stacey , Smith, Lacey A. , Boesch, Sylvia , Prentice, Anna Jenne , Hommersom, Marina P. , Vanoye, Carlos G. , Nothnagel, Michael , Palotie, Aarno V. , George, Alfred L. , Zárate, Yuri A. , Brunklaus, Andreas , Traynelis, Stephen F. , Lemke, Johannes R.

Mayo Clinic

No container title available | March 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.05.26347086 | PMID 41822692 Get It

Abstract Rare Mendelian disorders affect 300-400 million people globally. Although genetic testing has become widely adopted, gene-specific evidence for tailored variant interpretation remains scattered across resources. We present Gene Portals, a framework for gene-centered multimodal knowledge bases that co-localize expert-harmonized clinical data, functional assays, population variation, structural annotations and gene-specific ACMG/AMP specifications within a single resource. A modular interface integrates this unified evidence with VCEP-refined ACMG specifications to enable automated gene-specific variant classification, infer molecular mechanisms, and support cross-gene analyses. We demonstrate the framework’s utility across five Gene portals spanning eleven neurodevelopmental disorder-associated genes, integrating data from 4,423 individuals with 2,838 unique variants, 36,149 ClinVar submissions, and 1,044 expert-curated molecular readouts. By organizing evidence that is otherwise dispersed across multiple sources into a unified, queryable framework, the SCN, GRIN, CACNA1A, SATB2 and SLC6A1 Gene Portals became widely used community resources and provide an extensible template for standardized rare-disease variant interpretation and mechanism-aware discovery.
An intra-patient contemporaneous comparison of 18 F-piflufolastat and 18 F-flotufolastat urinary radioactivity and local and pelvic region detection rates
Helfand, B.R., Andrews, Jack R. , Kuo, Phillip H. , Gartrell, Benjamin A. , Josephson, David, Saltzstein, Daniel R. , Pathak, Ram , Shore, Neal D., Sykes, James, Penny, Ross, Cohen, Todd, Nordquist, Luke, Purysko, Andrei Saraiva , Shore, Neal D. , Penny, Ross

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 32-32

10.1200/jco.2026.44.7_suppl.32 Get It

32 Background: PET-based radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have become the mainstay of prostate cancer imaging; however, high urinary radioactivity from these primarily renally cleared compounds may obscure tumors in the prostate and peri-ureteric regions. We conducted the first intra-patient comparator study to assess the urinary radioactivity of two 18 F-labelled PSMA-PET radiopharmaceuticals, 18 F-piflufolastat and 18 F-flotufolastat. Methods: This multicenter, prospective, intra-patient comparator study (NCT06604442) enrolled men ≥ 18 years with low PSA (≤ 0.5 ng/mL) biochemical recurrence of prostate cancer ≥ 6 months after radical prostatectomy with undetectable PSA post-surgery, scheduled for a standard-of-care (SoC) 18 F-piflufolastat PET. Patients had a SoC PET/CT after IV 18 F-piflufolastat (target dose 333 MBq), and a second PET/CT 1–10 days later after IV 18 F-flotufolastat (target dose 296 MBq), both scans started approximately 60 min after administration and used the same scanner. The primary endpoint was the difference in urinary bladder radioactivity (mean standardized uptake value [SUV mean ]) between 18 F-piflufolastat PET and 18 F-flotufolastat PET. Secondary endpoints included patient and region-level detection rates (DR) for each radiopharmaceutical. Images were interpreted by two blinded central readers, with a third to resolve disagreements, allowing majority read results. Results: Between Oct 2024 and Jun 2025, 55 patients (mean PSA, 0.28 [range 0.09–0.50] ng/mL) were included in the primary efficacy analysis. Median bladder SUV mean was significantly higher with 18 F-piflufolastat (29.0; interquartile range [IQR], 18.9–40.8) than 18 F-flotufolastat (10.9; IQR, 6.0–18.5) with a median difference of 15.1 (IQR, 8.5–27.0; p<0.001 [Wilcoxon signed-rank test]). The patient-level DR was 27.3% (15/55) for 18 F-piflufolastat and 45.5% (25/55) for 18 F-flotufolastat (majority read). Among the 21 patients with very low PSA levels (≤ 0.2 ng/mL), 38.1% had a positive 18 F-piflufolastat scan compared with 52.4% for 18 F-flotufolastat scans (majority read). Regional and sub-regional DRs are shown in the table. Conclusions: In this intra-patient study, 18 F-flotufolastat showed significantly lower urinary radioactivity, and a higher overall DR than 18 F-piflufolastat indicating it may offer improved image assessment in regions close to the bladder. Clinical trial information: NCT06604442 . Region 18 F-Piflufolastat DR* n (%)N=55 18 F-Flotufolastat DR*n (%)N=55 Prostate bed 6 (10.9) 10 (18.2) Vesicourethral anastomosis 1 (1.8) 4 (7.3) Retrovesical 2 (3.6) 2 (3.6) Remnant seminal vesicles/ lateral surgical margin 2 (3.6) 4 (7.3) Pelvic lymph nodes 8 (14.5) 9 (16.4) Majority read. *≥ 1 PET positive lesion.
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2
Apostol, Adriana Ionelia , Gronwald, J., Cybulski, C., Kim, Raymond H. , Møller, P., Karlan, B., Bordeleau, Louise , Schrader, Intan , Cajal, Teresa Ramón y , Pal, Tuya, Eisen, Andrea, Singer, Christian F., Couch, Fergus J., Zakalik, Dana , Metcalfe, Kelly , Olopade, Olufunmilayo, Tung, Nadine, Fruscio, R, Foulkes, William D., Sun, P., Lubinski, J., Narod, Steven A., Sweet, Kevin , Elser, Christine , Panchal, Seema, Wiesner, Georgia L. , Armel, Susan, Steele, Linda, Serfas, Kim, Cullinane, Carey A., Reilly, Robert E., Mercer, L J, Dungan, Jeffrey R., Cohen, Stephanie, Neuhausen, Susan, Sun, Sophie, Blum, Joanne L., Stempa, Klaudia , Graham, Tracy Ann, Seca, Marta , Marchette, Martina Delle , Dell'Oro, Cristina, Alfonso, Rosa Moreno, Lopez, Consol, Cusco, Francesco, Karlan, Beth Y. , Schrader, Kasmintan A. , Eisen, Andrea , Apostol, Adriana I , Cybulski, Cezary , Karlan, Beth Y , Ramón Y Cajal, Teresa , Singer, Christian F , Couch, Fergus J. , Olopade, Olufunmilayo I , Tung, Nadine , Fruscio, Robert , Foulkes, William D , Aeilts, Amber M , Lubinski, Jan , Narod, Steven A , Kotsopoulos, Joanne , Metcalfe, Kelly A , Eisen, Andrea , Bordeleau, Louise , Kim, Raymond H , Cybulski, Cezary , Møller, Pål , Pal, Tuya , Singer, Christian F. , Couch, Fergus J. , Olopade, Olufunmilayo I. , Tung, Nadine , Foulkes, William D. , Aeilts, Amber M. , Lubiński, Jan , Narod, Steven A. , Kotsopoulos, Joanne , Steele, Linda, Saal, Howard M. , Rayson, Daniel , Mercer, Leanne, Cohen, Stephanie, Neuhausen, Susan L, Senter, Leigha , Blum, Joanne Lorraine , Negri, Serena , Dell’Oro, Cristina, Inzoli, Alessandra , Alfonso, Rosa

Mayo Clinic

Journal of Clinical Oncology | February 28, 2026 | Volume: 44 | Issue: 10 | Pages: 883-892

10.1200/jco-25-01648 | PMID 41762747 Get It

PURPOSE BRCA carriers face high risks of developing both breast and ovarian/fallopian tube cancers (hereafter referred to as ovarian ). Among BRCA carriers with ovarian cancer, it is not clear whether the risk of breast cancer is sufficiently high that risk-reducing mastectomy should be offered. This study aimed to assess the risk of breast cancer BRCA carriers after a diagnosis of ovarian cancer. METHODS We included women with a pathogenic/likely pathogenic variant in BRCA1 or BRCA2 , a diagnosis of ovarian cancer, and no other cancer history and no risk-reducing bilateral mastectomy. Women were followed for incident breast cancer from the date of ovarian cancer diagnosis or the date of baseline questionnaire, whichever came last. The 5-, 10-, and 15-year cumulative risks of breast cancer were compared for women with ovarian cancer and an age-matched set of control women without ovarian cancer. RESULTS A total of 960 participants with ovarian cancer were identified (814 BRCA1 and 146 BRCA2 carriers). After a mean follow-up of 4.9 years, 41 women (4.3%) developed breast cancer, at a mean age at diagnosis of 57.5 years (range, 39-74). Actuarial cumulative breast cancer risks after ovarian cancer were 4.4%, 8.9%, and 11.5% at 5, 10, and 15 years, respectively. Only three breast cancer–related deaths occurred. Among 741 age-matched BRCA carriers without ovarian cancer, actuarial cumulative risks of breast cancer were 20.9%, 38.6%, and 47.2% at 5, 10, and 15 years, respectively. The hazard ratio for breast cancer, after an ovarian cancer diagnosis, compared with no ovarian cancer, was 0.18 ([95% CI, 0.12 to 0.27]; P < .0001). CONCLUSION After ovarian cancer, BRCA carriers have a relatively low risk of breast cancer. Risk-reducing mastectomy should not be recommended routinely, but might be considered for long-term survivors. Magnetic resonance imaging surveillance and/or mammography is a realistic alternative.
Multisociety multispecialty position statement on corticosteroid injections and influenza and COVID-19 vaccine administration
Benzon, Honorio T, FitzGerald, John, Flaherty, John P., Cohen, Steven Paul, Doshi, Tina L , Mina, Maged, Abd-Elsayed, Alaa, Eckmann, Maxim , Elmofty, Dalia , Hirsch, Joshua Adam, Hoang, Thanh Tuan , Manchikanti, Laxmaiah, Pino, Carlos, Rana, Maunak V., Rivera, Jessica , Shah, Shalini, Schneider, Byron J. , Souza, Dmitri , Stout, Alison, Maus, Tim, Cohen, Steven P. , Benzon, Honorio T. , FitzGerald, John , Benzon, Honorio T , Cohen, Steven P , Chadwick, Andrea , Hunt, Christine , Nagpal, Ameet S , Nelson, Ariana M , Pino, Carlos A , Provenzano, David Anthony , Shankar, Hariharan , Wasan, Ajay D , Narouze, Samer , Doshi, Tina L , FitzGerald, John D , FitzGerald, John, Abdi, Salahadin , Abd-Elsayed, Alaa A , Manchikanti, Laxmaiah , Nagpal, Ameet , Nelson, Ariana M. , Pino, Carlos A. , Provenzano, David , Rivera, Jessica, Shankar, Hariharan , Shanthanna, Harsha , Wasan, Ajay D. , Narouze, Samer , Maus, Timothy P.

Mayo Clinic

Regional Anesthesia & Pain Medicine | February 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-107556

10.1136/rapm-2025-107556 | PMID 41760373 Get It

Background Corticosteroid injections (CSIs) are widely employed for chronic pain. These injections include peripheral nerve blocks and trigger point injections, injections of large appendicular joints, the axial facet and sacroiliac joints, and the epidural space. These injections may be performed in patients who have been recently vaccinated or plan to be vaccinated. This multisociety multispecialty position statement aims to develop evidence-based statements and recommendations (SRs) on the safe interval between CSIs and COVID-19 and influenza vaccine administration. Methods Development of the position statement was approved by the American Society of Regional Anesthesia and Pain Medicine Board of Directors and several other societies that agreed to participate. The scope of the SRs was agreed on to include the efficacy of COVID-19 and influenza vaccines, adverse events related to the CSIs, specifically the effect of CSIs on the hypothalamic–pituitary axis, incidence of COVID-19 in patients who had CSIs during the pandemic, incidence of influenza in patients who had CSIs during the influenza season, and recommend a reasonable interval between CSIs and COVID-19 and influenza vaccination 20 mg/day of prednisone s. Experts were assigned topics to perform a comprehensive literature review and draft SRs, which were refined and voted for consensus (≥75% agreement) using a modified Delphi process. A modified version of the US Preventive Services Task Force grading of evidence and strength of recommendation was followed. Results All SRs were approved by all participants after four rounds of discussion. The Practice Guidelines Committees and Boards of Directors of the participating societies also approved all SRs. If a vaccine has been recently administered or planned, then for non-urgent indications, the CSI should be offered at least 1 week before or after vaccine administration. For healthy patient(s), CSI, or vaccine administration may be performed without a 7-day interval after informed discussion with the patient and consent regarding the risk of blunted vaccine efficacy. For non-healthy patients, shared decision-making should include discussion of diminished vaccine effectiveness and the possibility of influenza or COVID-19 infection. Conclusions In this position statement, we provide recommendations on the optimal timing between CSIs and COVID-19 or influenza vaccine.
Recommendations for the Deprescribing of Psychotropic Medications
Goldberg, Joseph F. , McIntyre, R. S., Freeman, Marlene P. , Mago, Rajnish, Citrome, Leslie, Rosenblat, Joshua D., Thase, Michael E., Tohen, Mauricio, Vieta, Eduard, Malhi, Gin S, Sajatovic, M., Shelton, Richard C. , Macaluso, Matthew , Berk, Michael, Perlis, Roy H., Ostacher, Michael J., Khan, Arifulla, Sanacora, Gerard , Kane, John M., D, Goodman, Nierenberg, Andrew A., Correll, Christoph U., Kupka, R. W., Kasper, Siegfried, Furukawa, Toshi A., Davis, Lori L., Aaronson, Scott T., Gitlin, Michael , Jha, Manish K., Cohen, Lawrence J. , Papakostas, George I. , Mitchell, Philip B., Gorwood, P., Gupta, Swapnil , Frye, Mark A., Young, A. H., Zohar, Joseph, Steingard, Sandra , Zarate, Carlos A., Clayton, Anita H. , Shelton, Richard C. , Young, Allan H. , Ostacher, Michael J. , Jha, Manish K. , Young, Allan H , Jha, Manish K , Ostacher, Michael J , McIntyre, Roger S. , Swartz, Holly A. , Citrome, Leslie , Rosenblat, Joshua D. , Thase, Michael E. , Tohen, Mauricio , Vieta, Eduard , Malhi, Gin S. , Sajatovic, Martha, Berk, Michael , Perlis, Roy H , Iosifescu, Dan Vlad , Rubio, Jose M , Kane, John M. , Nierenberg, Andrew A. , Correll, Christoph Ulrich , Kupka, Ralph , Kasper, Siegfried , Furukawa, Toshi A , Aaronson, Scott T. , Mitchell, Philip B , Gorwood, Philip , Frye, Mark A. , Zohar, Joseph , Zarate, Carlos A.

Mayo Clinic

JAMA Network Open | February 25, 2026 | Volume: 9 | Issue: 2 | Pages: e260043

10.1001/jamanetworkopen.2026.0043 | PMID 41739481 Get It

Importance There is a need for greater recognition of clinical psychopharmacology endpoints, including instances where specific psychotropic medications may become unnecessary, redundant, contradictory, or otherwise inappropriate and therefore merit deprescribing. Objective To address circumstances warranting psychotropic medication deprescribing. Evidence Review The American Society of Clinical Psychopharmacology convened a panel of 45 international psychopharmacology experts who developed and completed a multiround Delphi survey and conducted a focused literature review between January and May of 2025, in order to identify areas of consensus or disagreement on key aspects of the deprescribing of psychotropic medications. These included collaborative risk-benefit assessments with patients; pharmacokinetic and pharmacodynamic factors; pharmacogenomics; distinguishing redundant or conflictual from complementary mechanisms of action; managing adverse effects; assuring medication adherence; drug tolerance or tachyphylaxis; medication misuse; and the psychological context and ramifications of deprescribing. Findings Consensus was achieved on 44 of 50 final Delphi statements (88%). Panelists unanimously agreed that components of a pharmacotherapy regimen should undergo periodic review to ensure that treatments target relevant symptoms and have favorable risk-benefit ratios. Key points of consensus were that deprescribing: (1) should not occur without first assessing medication adherence; (2) merits consideration if less than partial therapeutic response is apparent, or if treatment goals have been reached and relapse prevention is not a long-term objective; (3) involves psychological ramifications that warrant attention; (4) should be followed by close clinical monitoring; and (5) risk-benefit decisions should ideally involve active patient participation within a shared decision-making model. Conclusions and Relevance Through this Consensus Statement, the Task Force identified circumstances in which the selective elimination of certain psychotropic medications may be clinically indicated. Empirical trials are needed to assess the implementation of deprescribing protocols and gauge their safe, effective, and acceptable outcomes.